SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

02/03/2026

1

Speculative Buy

$0.99

52.31%

The first half result from SomnoMed places the business in a strong position to achieve the "lower end of guidance" Morgans notes. FY26 revenue guidance is $119-126m and EBITDA $10-12m.  Around half of revenue and the majority of EBITDA have already been achieved in the first half.

The broker continues to believe the stock is undervalued even against conservative assumptions, and the weakness in the share price, despite intact fundamentals, provides an opportunity. Speculative Buy rating maintained. Target is $0.99.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.60 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.90 cents.

10/03/2026

1

Buy

$1.00

53.85%

SomnoMed delivered first half results that were in line with expectations and management has maintained FY26 guidance.

Canaccord Genuity points out the FY25 result marked a transition to sustainable earnings growth and, if the behaviour of CPAP manufacturers is any guide, the sleep industry expects a step change in volumes amid tech generated and GLP-1 associated demand.

Commentary suggests the company may already be experiencing passive upside from both trends.

The monitoring components of RA have already been cleared by the FDA and this could mean the company becomes more active in this channel. Buy rating and $1 target unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.20 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.70 cents.